Richard M. Pope, MD
Mabel Green Myers Professor of Medicine
Chief, Division of Rheumatology
Northwestern University Medical School
Chicago, IL
What do clinical trials tell us about what strategies are optimal for RA patients who are inadequate responders to DMARDs and/or biologic therapy?
What are the pivotal mechanisms by which IL-6 contributes to the pathogenesis of RA?
What are the pivotal mechanisms by which IL-6 contributes to the pathogenesis of RA?
How do you identify high risk patients who are likely to benefit from biological therapy?
How do you identify high risk patients who are likely to benefit from biological therapy?
How do you initiate DMARD therapy and what agents or combinations do you employ?
How do you initiate DMARD therapy and what agents or combinations do you employ?
In patients at risk for or a previous history of serious infection, are there some biologic agents that seem to lower the risk of such a complication?